PDF herunterladen
Semin Respir Crit Care Med 2001; 22(5): 559-580
DOI: 10.1055/s-2001-18428
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Immunosuppressive Drugs and Novel Strategies to Prevent Acute and Chronic Allograft Rejection

Kathleen D. Lake
  • Clinical Research and Transplant Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, and Departments of Medicine and Surgery, University of Michigan Medical School, Ann Arbor, Michigan
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
14. November 2001 (online)

    Lizenzen und Reprints

ABSTRACT

Maintenance immunosuppression for lung transplantation includes cyclosporine or tacrolimus, mycophenolate mofetil or azathioprine, and prednisone. Some centers rely on induction agents including OKT3 (murine monoclonal antibody, OKT3), ATG (antithymocyte globulin), or thymoglobulin. In addition, a number of new agents including sirolimus (SRL) and the interleukin (IL)-2 receptor antagonists, daclizumab and basiliximab, have become available. Management of chronic rejection typically consists of augmented immunosuppression using many of the standard agents, and other potent agents such as methotrexate or cytoxan or more novel strategies including photopheresis, radiation, and total lymphoid irradiation (TLI).

KEYWORD

Immunosuppressants for lung transplantation - rejection therapy - treatment of obliterative bronchiolitis

REFERENCES

  • 1 Sollinger H W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.  Transplantation . 1995;  60 225-232
    CrossrefPubMedGoogle Scholar
  • 2 Anonymous. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group [see comments].  Lancet . 1995;  345 1321-1325
    PubMedGoogle Scholar
  • 3 Anonymous. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group [see comments].  Transplantation . 1996;  61 1029-1037
    PubMedGoogle Scholar
  • 4 Kahan B D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune U.S. Study Group.  Lancet . 2000;  356 194-202
    CrossrefPubMedGoogle Scholar
  • 5 Brennan D C, Flavin K, Lowell J A. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients [published erratum appears in Transplantation 1999 May 27;67(10):1386].  Transplantation . 1999;  67 1011-1018
    PubMedGoogle Scholar
  • 6 Kahan B D, Rajagopalan P R, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.  Transplantation . 1999;  67 276-284
    PubMedGoogle Scholar
  • 7 Johnson C, Ahsan N, Gonwa T. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.  Transplantation . 2000;  69 834-841
    PubMedGoogle Scholar
  • 8 Miller J, Mendez R, Pirsch J D, Jensik S C. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/ MMF Dose-Ranging Kidney Transplant Study Group.  Transplantation . 2000;  69 875-880
    PubMedGoogle Scholar
  • 9 Vincenti F, Kirkman R, Light S. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group [see comments].  N Eng J Med . 1998;  338 161-165
    CrossrefPubMedGoogle Scholar
  • 10 Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.  Transplant Proc . 1998;  30 2155-2158
    CrossrefPubMedGoogle Scholar
  • 11 Griffith B P, Bando K, Hardesty R L. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.  Transplantation . 1994;  57 848-851
    PubMedGoogle Scholar
  • 12 Corris P, Glanville A, McNeil K. One-year analysis of an ongoing international randomized study of mycophenolate mofetil (MMF) vs azathioprine (AZA) in lung transplantation.  J Heart Lung Transplant . 2001;  20 149-150
    PubMedGoogle Scholar
  • 13 Keenan R J, Konishi H, Kawai A. Clinical trial of tacrolimus versus cyclosporine in lung transplantation [see comments].  Ann Thorac Surg . 1995;  60 580-585
    CrossrefPubMedGoogle Scholar
  • 14 Treede H, Kepetko W, Reichenspurner H. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols.  J Heart Lung Transplant . 2001;  20 511-517
    CrossrefPubMedGoogle Scholar
  • 15 Hosenpud J D, Bennett L E, Keck B M, Boucek M M, Novick R J. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000.  J Heart Lung Transplant . 2000;  19 909-931
    CrossrefPubMedGoogle Scholar
  • 16 Valentine V G, Robbins R C, Wehner J H, Patel H R, Berry G J, Theodore J. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts [see comments].  Chest . 1996;  109 1184-1189
    CrossrefPubMedGoogle Scholar
  • 17 Keck B M, Bennett L E, Rosendale J, Daily O P, Novick R J, Hosenpud J D. Worldwide Thoracic Organ Transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. In: Cecka L, Terasaki P, eds. Clinical Transplants 1999 Los Angeles, Calif.: UCLA Immunogenetics Center 1999: 35-49
    Google Scholar
  • 18 Kahan B D. Cyclosporine.  N Engl J Med . 1989;  321 1725-1738
    CrossrefPubMedGoogle Scholar
  • 19 Matsuda S, Koyasu S. Mechanisms of action of cyclosporine.  Immunopharmacology . 2000;  47 119-125
    CrossrefPubMedGoogle Scholar
  • 20 Faulds D, Goa K L, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.  Drugs . 1993;  45 953-1040
    CrossrefPubMedGoogle Scholar
  • 21 Kahan B D, Dunn J, Fitts C. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.  Transplantation . 1995;  59 505-511
    PubMedGoogle Scholar
  • 22 Lown K S, Kolars J C, Thummel K E. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test.  Drug Metab Dispos . 1994;  22 947-955
    PubMedGoogle Scholar
  • 23 Watkins P B. Drug metabolism by cytochromes P450 in the liver and small bowel.  Gastroenterol Clin North Am . 1992;  21 511-526
    PubMedGoogle Scholar
  • 24 Aoyama T, Yamano S, Waxman D J. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.  J Biol Chem . 1989;  264 10388-10395
    PubMedGoogle Scholar
  • 25 Wrighton S A, Ring B J, Watkins P B, VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family.  Mol Pharmacol . 1989;  36 97-105
    PubMedGoogle Scholar
  • 26 Watkins P B, Wrighton S A, Maurel P. Identification of an inducible form of cytochrome P-450 in human liver.  Proc Natl Acad Sci USA . 1985;  82 6310-6314
    PubMedGoogle Scholar
  • 27 Kolars J C, Awni W M, Merion R M, Watkins P B. First-pass metabolism of cyclosporin by the gut.  Lancet . 1991;  338 1488-1490
    CrossrefPubMedGoogle Scholar
  • 28 Kolars J, Schrniedlin-Ren P, Schuetz J, Ghosh M, Dobbins W, Watkins P. Expression of P450IIIA4 in duodenal mucosa: interpatient variability and regulation in cultured explants.  Gastroenterology . 1991;  100 A221
    PubMedGoogle Scholar
  • 29 Lown K S, Mayo R R, Leichtman A B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.  Clin Pharmacol Ther . 1997;  62 248-260
    CrossrefPubMedGoogle Scholar
  • 30 Roninson I B, Chin J E, Choi K G. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.  Proc Natl Acad Sci USA . 1986;  83 4538-4542
    PubMedGoogle Scholar
  • 31 Pavelic Z P, Reising J, Pavelic L, Kelley D J, Stambrook P J, Gluckman J L. Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues.  Arch Otolaryngol Head Neck Surg . 1993;  119 753-757
    PubMedGoogle Scholar
  • 32 Keown P, Landsberg D, Halloran P. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.  Transplantation . 1996;  62 1744-1752
    PubMedGoogle Scholar
  • 33 Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.  Transplantation . 1999;  68 55-62
    PubMedGoogle Scholar
  • 34 Mahalati K, Lawen J, Kiberd B, Belitsky P. Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period?.  J Urol . 2000;  163 37-41
    PubMedGoogle Scholar
  • 35 Freeman D, Grant D, Levy G. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients.  Ther Drug Monit . 1995;  17 213-216
    PubMedGoogle Scholar
  • 36 Oellerich M, Armstrong V W, Schutz E, Shaw L M. Therapeutic drug monitoring of cyclosporine and tacrolimus: update on Lake Louise Consensus Conference on cyclosporin and tacrolimus.  Clin Biochem . 1998;  31 309-316
    PubMedGoogle Scholar
  • 37 Lake K D, Canafax D M. Important interactions of drugs with immunosuppressive agents used in transplant recipients.  J Antimicrob Chemother . 1995;  36 11-22
    PubMedGoogle Scholar
  • 38 Mignat C. Clinically significant drug interactions with new immunosuppressive agents.  Drug Saf . 1997;  16 267-278
    CrossrefPubMedGoogle Scholar
  • 39 Breidenbach T, Hoffmann M W, Becker T, Schlitt H, Klempnauer J. Drug interaction of St John's wort with cyclosporin.  Lancet . 2000;  355 1912
    PubMedGoogle Scholar
  • 40 Ruschitzka F, Meier P J, Turina M, Luscher T F, Noll G. Acute heart transplant rejection due to Saint John's wort.  Lancet . 2000;  355 548-549
    CrossrefPubMedGoogle Scholar
  • 41 Hebert M F, Roberts J P, Prueksaritanont T, Benet L Z. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction.  Clin Pharmacol Ther . 1992;  52 453-457
    PubMedGoogle Scholar
  • 42 Gomez D Y, Wacher V J, Tomlanovich S J, Hebert M F, Benet L Z. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.  Clin Pharmacol Ther . 1995;  58 15-19
    CrossrefPubMedGoogle Scholar
  • 43 Gupta S K, Bakran A, Johnson R W, Rowland M. Cyclosporin-erythromycin interaction in renal transplant patients.  Br J Clin Pharmacol . 1989;  27 475-481
    CrossrefPubMedGoogle Scholar
  • 44 Miura T, Iwasaki M, Komori M. Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics.  J Antimicrob Chemother . 1989;  24 551-559
    PubMedGoogle Scholar
  • 45 Valantine H, Keogh A, McIntosh N, Hunt S, Oyer P, Schroeder J. Cost containment: coadministration of diltiazem with cyclosporine after heart transplantation.  J Heart Lung Transplant . 1992;  11 1-8
    PubMedGoogle Scholar
  • 46 Neumayer H H, Wagner K. Diltiazem and economic use of cyclosporin.  Lancet . 1986;  2 523
    PubMedGoogle Scholar
  • 47 Pochet J M, Pirson Y. Cyclosporin-diltiazem interaction.  Lancet . 1986;  1 979
    PubMedGoogle Scholar
  • 48 Sketris I S, Methot M E, Nicol D, Belitsky P, Knox M G. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients.  Ann Pharmacother . 1994;  28 1227-1231
    PubMedGoogle Scholar
  • 49 Lindholm A, Henricsson S. Verapamil inhibits cyclosporin metabolism.  Lancet . 1987;  1 1262-1263
    PubMedGoogle Scholar
  • 50 Tortorice K L, Heim-Duthoy K L, Awni W M, Rao K V, Kasiske B L. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients.  Ther Drug Monit . 1990;  12 321-328
    PubMedGoogle Scholar
  • 51 Wrighton S A, Ring B J. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.  Pharm Res . 1994;  11 921-924
    CrossrefPubMedGoogle Scholar
  • 52 Christians U, First M R, Benet L Z. Recommendations for bioequivalence testing of cyclosporine generics revisited.  Ther Drug Monit . 2000;  22 330-345
    CrossrefPubMedGoogle Scholar
  • 53 Bennett W M. Renal complications after heart transplantation.  Transplant Proc . 1999;  31 88
    CrossrefPubMedGoogle Scholar
  • 54 De Mattos M A, Olyaei A J, Bennett W M. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future [editorial].  Am J Kidney Dis . 2000;  35 333-346
    CrossrefPubMedGoogle Scholar
  • 55 Esposito C, Semeraro L, Bellotti N. Risk factors for chronic renal dysfunction in cardiac allograft recipients.  Nephron . 2000;  84 21-28
    CrossrefPubMedGoogle Scholar
  • 56 Frimat L, Villemot J P, Cormier L. Treatment of end-stage renal failure after heart transplantation.  Nephrol Dial Transplant . 1998;  13 2905-2908
    PubMedGoogle Scholar
  • 57 Kobashigawa J A, Kasiske B L. Hyperlipidemia in solid organ transplantation.  Transplantation . 1997;  63 331-338
    PubMedGoogle Scholar
  • 58 Sahar G, Stamler A, Berman M. Role of cyclosporine in inducing hyperuricemia in heart transplant patients.  Transplant Proc . 2000;  32 729-730
    CrossrefPubMedGoogle Scholar
  • 59 Singer D R, Jenkins G H. Hypertension in transplant recipients.  J Hum Hypertens . 1996;  10 395-402
    PubMedGoogle Scholar
  • 60 Wilkinson A H, Cohen D J. Renal failure in the recipients of nonrenal solid organ trasplants.  J Am Soc Nephrol . 1999;  10 1136-1144
    PubMedGoogle Scholar
  • 61 Shapiro R. Tacrolimus in solid organ transplantation: an update.  Transplant Proc . 1999;  31 2203-2205
    CrossrefPubMedGoogle Scholar
  • 62 Plosker G L, Foster R H. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.  Drugs . 2000;  59 323-389
    CrossrefPubMedGoogle Scholar
  • 63 Zhang J G, Walmsley M W, Moy J V. Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: implications for the development of obliterative bronchiolitis after lung transplantation.  Transpl Int . 1998;  11(suppl 1) S325-S327
    CrossrefPubMedGoogle Scholar
  • 64 Bicknell G R, Williams S T, Shaw J A, Pringle J H, Furness P N, Nicholson M L. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants.  Br J Surg . 2000;  87 1569-1575
    CrossrefPubMedGoogle Scholar
  • 65 Mohamed M A, Robertson H, Booth T A, Balupuri S, Kirby J A, Talbot D. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus.  Transplantation . 2000;  69 1002-1005
    PubMedGoogle Scholar
  • 66 Christians U, Kruse C, Kownatzki R. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites.  Transplant Proc . 1991;  23 940-941
    PubMedGoogle Scholar
  • 67 Christians U, Braun F, Kosian N. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients.  Transplant Proc . 1991;  23 2741-2744
    PubMedGoogle Scholar
  • 68 Iwasaki K, Shiraga T, Nagase K. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone.  Drug Metab Dispos . 1993;  21 971-977
    PubMedGoogle Scholar
  • 69 Venkataramanan R, Swaminathan A, Prasad T. Clinical pharmacokinetics of tacrolimus.  Clin Pharmacokinet . 1995;  29 404-430
    CrossrefPubMedGoogle Scholar
  • 70 Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schafer A, van Hooff J. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients.  Transplant Proc . 1998;  30 1271-1273
    CrossrefPubMedGoogle Scholar
  • 71 Hong J C, Kahan B D. Immunosuppressive agents in organ transplantation: past, present, and future.  Semin Nephrol . 2000;  20 108-125
    PubMedGoogle Scholar
  • 72 Ihara H, Shinkuma D, Ichikawa Y, Nojima M, Nagano S, Ikoma F. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients: importance of trough level as a practical indicator.  Int J Urol . 1995;  2 151-155
    PubMedGoogle Scholar
  • 73 Jusko W J, Piekoszewski W, Klintmalm G B. Pharmacokinetics of tacrolimus in liver transplant patients.  Clin Pharmacol Ther . 1995;  57 281-290
    CrossrefPubMedGoogle Scholar
  • 74 Regazzi M B, Rinaldi M, Molinaro M. Clinical pharmacokinetics of tacrolimus in heart transplant recipients.  Ther Drug Monit . 1999;  21 2-7
    CrossrefPubMedGoogle Scholar
  • 75 Boswell G W, Bekersky I, Fay J. Tacrolimus pharmacokinetics in BMT patients.  Bone Marrow Transplant . 1998;  21 23-28
    CrossrefPubMedGoogle Scholar
  • 76 Laskow D A, Vincenti F, Neylan J F, Mendez R, Matas A J. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group.  Transplantation . 1996;  62 900-905
    PubMedGoogle Scholar
  • 77 Floren L C, Bekersky I, Benet L Z. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole.  Clin Pharmacol Ther . 1997;  62 41-49
    CrossrefPubMedGoogle Scholar
  • 78 Furlan V, Perello L, Jacquemin E, Debray D, Taburet A M. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients.  Transplantation . 1995;  59 1217-1218
    PubMedGoogle Scholar
  • 79 Paterson D L, Singh N. Interactions between tacrolimus and antimicrobial agents.  Clin Infect Dis . 1997;  25 1430-1440
    PubMedGoogle Scholar
  • 80 Fugh-Berman A. Herb-drug interactions.  Lancet . 2000;  355 134-138
    CrossrefPubMedGoogle Scholar
  • 81 Glanemann M, Klupp J, Langrehr J M. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A.  Transplant Proc . 2000;  32 522-523
    CrossrefPubMedGoogle Scholar
  • 82 Smak Gregoor J P, van Gelder T, Hesse C J, van der Mast J B, van Besouw M N, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.  Nephrol Dial Transplant . 1999;  14 706-708
    PubMedGoogle Scholar
  • 83 VanGelder T, Klupp J, Barten M. Coadministration of tacrolimus (FK) and mycophenolate mofetil (MMF) does not increase mycophenolic acid (MPA) exposure, but coadministration of cyclosporine (CsA) and MMF inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure (abstract no. A3622).  J Am Soc Nephrol . 1999;  10 A3622
    PubMedGoogle Scholar
  • 84 Hariharan S, Tomlanovich S J, Filo R S, Dessimox M, Wisemandle W, Townsend R W. Pharmacokinetics (PK) and tolerability of tacrolimus and sirolimus combination therapy in stable renal transplant recipients.  Am J Transplant . 2001;  1(suppl) 406
    PubMedGoogle Scholar
  • 85 Canafax D M. Minimizing cyclosporine concentration variability to optimize transplant outcome.  Clin Transplant . 1995;  9 1-13
    PubMedGoogle Scholar
  • 86 Bennett W M. The nephrotoxicity of immunosuppressive drugs.  Clin Nephrol . 1995;  43(suppl 1) S3-S7
    PubMedGoogle Scholar
  • 87 Meiser B M, Uberfuhr P, Fuchs A. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection.  J Heart Lung Transplant . 1998;  17 782-788
    PubMedGoogle Scholar
  • 88 Johnson C, Ahsan N, Gonwa T. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after kidney transplantation.  Transplantation . 2000;  69 834-841
    PubMedGoogle Scholar
  • 89 Pham S M, Kormos R L, Hattler B G. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results.  J Thorac Cardiovasc Surg . 1996;  111 764-772
    PubMedGoogle Scholar
  • 90 Meiser B M, Uberfuhr P, Fuchs A. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.  J Heart Lung Transplant . 1997;  16 795-800
    PubMedGoogle Scholar
  • 91 Taylor D O, Barr M L, Radovancevic B. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.  J Heart Lung Transplant . 1999;  18 336-345
    PubMedGoogle Scholar
  • 92 Reichart B, Meiser B, Vigano M. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results-European Tacrolimus Multicenter Heart Study Group.  J Heart Lung Transplant . 1998;  17 775-781
    PubMedGoogle Scholar
  • 93 Horning N R, Lynch J P, Sundaresan S R, Patterson G A, Trulock E P. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation.  J Heart Lung Transplant . 1998;  17 761-767
    PubMedGoogle Scholar
  • 94 Kesten S, Chaparro C, Scavuzzo M, Gutierrez C. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome.  J Heart Lung Transplant . 1997;  16 905-912
    PubMedGoogle Scholar
  • 95 Ross D J, Lewis M I, Kramer M, Vo A, Kass R M. FK 506 `rescue' immunosuppression for obliterative bronchiolitis after lung transplantation.  Chest . 1997;  112 1175-1179
    PubMedGoogle Scholar
  • 96 Chan G L, Canafax D M, Johnson C A. The therapeutic use of azathioprine in renal transplantation.  Pharmacotherapy . 1987;  7 165-177
    PubMedGoogle Scholar
  • 97 Lin S N, Jessup K, Floyd M. Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients.  Transplantation . 1980;  29 290-294
    PubMedGoogle Scholar
  • 98 Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Tufveson G, Grefberg N. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients.  Int J Immunopharmacol . 1986;  8 1-11
    CrossrefPubMedGoogle Scholar
  • 99 Lennard L, Brown C B, Fox M, Maddocks J L. Azathioprine metabolism in kidney transplant recipients.  Br J Clin Pharmacol . 1984;  18 693-700
    PubMedGoogle Scholar
  • 100 Chan G L, Erdmann G R, Gruber S A, Matas A J, Canafax D M. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients.  J Clin Pharmacol . 1990;  30 358-363
    PubMedGoogle Scholar
  • 101 Woodson L C, Weinshilboum R M. Human kidney thiopurine methyltransferase: purification and biochemical properties.  Biochem Pharmacol . 1983;  32 819-826
    CrossrefPubMedGoogle Scholar
  • 102 Weinshilboum R M, Sladek S L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.  Am J Hum Genet . 1980;  32 651-662
    PubMedGoogle Scholar
  • 103 Szumlanski C L, Honchel R, Scott M C, Weinshilboum R M. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes.  Pharmacogenetics . 1992;  2 148-159
    PubMedGoogle Scholar
  • 104 Kennedy D T, Hayney M S, Lake K D. Azathioprine and allopurinol: the price of an avoidable drug interaction.  Ann Pharmacother . 1996;  30 951-954
    CrossrefPubMedGoogle Scholar
  • 105 Brooks R J, Dorr R T, Durie B G. Interaction of allopurinol with 6-mercaptopurine and azathioprine.  Biomedicine and Pharmacotherapy . 1982;  36 217-222
    PubMedGoogle Scholar
  • 106 Coffey J J, White C A, Lesk A B, Rogers W I, Serpick A A. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients.  Cancer Res . 1972;  32 1283-1289
    PubMedGoogle Scholar
  • 107 Lennard L, Murphy M F, Maddocks J L. Severe megaloblastic anaemia associated with abnormal azathioprine metabolism.  Br J Clin Pharmacol . 1984;  17 171-172
    PubMedGoogle Scholar
  • 108 Shapiro R, Jordan M L, Scantlebury V P. Alopecia as a consequence of tacrolimus therapy.  Transplantation . 1998;  65 1284
    PubMedGoogle Scholar
  • 109 Ushigome H, Yoshimura N, Okamoto M. Two cases of tacrolimus-induced alopecia following kidney transplantation.  Transplant Proc . 1999;  31 2885-2886
    CrossrefPubMedGoogle Scholar
  • 110 Sievers T M, Rossi S J, Ghobrial R M. Mycophenolate mofetil.  Pharmacotherapy . 1997;  17 1178-1197
    PubMedGoogle Scholar
  • 111 Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.  Drugs . 1996;  51 278-298
    PubMedGoogle Scholar
  • 112 Smak Gregoor J H P, de Sevaux G L R, Hene R J. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.  Transplantation . 1999;  68 1603-1606
    PubMedGoogle Scholar
  • 113 DeNofrio D, Goldberg L R, Loh E. Reduced mycophenolic acid concentrations are associated with an increased risk of rejection following heart transplantation.  Circulation . 1999;  100(18, suppl 5) 2770
    PubMedGoogle Scholar
  • 114 Meiser B M, Pfeiffer M, Schmidt D. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring.  J Heart Lung Transplant . 1999;  18 143-149
    PubMedGoogle Scholar
  • 115 Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients.  Br J Clin Pharmacol . 1996;  41 513-516
    CrossrefPubMedGoogle Scholar
  • 116 Morii M, Ueno K, Ogawa A. Impairment of mycophenolate mofetil absorption by iron ion.  J Clin Pharmacol Ther . 2000;  68 613-616
    PubMedGoogle Scholar
  • 117 Zucker K, Rosen A, Tsaroucha A. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy and analogous in vitro findings.  Transpl Immunol . 1997;  5 225-232
    PubMedGoogle Scholar
  • 118 Bullingham R E, Nicholls A J, Kamm B R. Clinical pharmacokinetics of mycophenolate mofetil.  Clin Pharmacokinet . 1998;  34 429-455
    CrossrefPubMedGoogle Scholar
  • 119 Kaplan B, Meier-Kriesche H U, Friedman G. The effect of renal insufficiency on mycophenolic acid protein binding.  J Clin Pharmacol . 1999;  39 715-720
    CrossrefPubMedGoogle Scholar
  • 120 Mathew T H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.  Transplantation . 1998;  65 1450-1454
    CrossrefPubMedGoogle Scholar
  • 121 Renlund D G, Gopinathan S K, Kfoury A G, Taylor D O. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment.  Clin Transplant . 1996;  10 136-139
    PubMedGoogle Scholar
  • 122 Taylor D O, Ensley R D, Olsen S L, Dunn D, Renlund D G. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation.  J Heart Lung Transplant . 1994;  13 571-582
    PubMedGoogle Scholar
  • 123 Kirklin J K, Bourge R C, Naftel D C. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.  J Heart Lung Transplant . 1994;  13 444-450
    PubMedGoogle Scholar
  • 124 Kobashigawa J, Miller L, Renlund D. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators [see comments].  Transplantation . 1998;  66 507-515
    CrossrefPubMedGoogle Scholar
  • 125 Hosenpud J D, Bennett L E. Mycophenolate mofetil compared to azathioprine improves survival in patients surviving the initial cardiac transplant hospitalization: an analysis of the joint ISHLT/UNOS Thoracic Registry.  J Heart Lung Transplant . 2000;  19 72
    PubMedGoogle Scholar
  • 126 Ross D J, Waters P F, Levine M, Kramer M, Ruzevich S, Kass R M. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience.  J Heart Lung Transplant . 1998;  17 768-774
    PubMedGoogle Scholar
  • 127 Zuckermann A, Birsan T, Thaghavi S. Mycophenolate mofetil in lung transplantation.  Transplant Proc . 1998;  30 1514-1516
    CrossrefPubMedGoogle Scholar
  • 128 O'Hair D P, Cantu E, McGregor C. Preliminary experience with mycophenolate mofetil used after lung transplantation.  J Heart Lung Transplant . 1998;  17 864-868
    PubMedGoogle Scholar
  • 129 Speich R, Boehler A, Thurnheer R, Weder W. Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: importance of dosage.  Transplantation . 1997;  64 533-535
    CrossrefPubMedGoogle Scholar
  • 130 Speich R, Boehler A, Russi E W, Weder W. A case report of a double-blind, randomized trial of inhaled steroids in a patient with lung transplant bronchiolitis obliterans.  Respiration . 1997;  64 375-380
    PubMedGoogle Scholar
  • 131 Whyte R I, Rossi S J, Mulligan M S. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation.  Ann Thorac Surg . 1997;  64 945-948
    CrossrefPubMedGoogle Scholar
  • 132 Zuckermann A, Klepetko W, Birsan T. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation.  J Heart Lung Transplant . 1999;  18 432-440
    PubMedGoogle Scholar
  • 133 Hricik D E. Withdrawal of immunosuppression: implications for composite tissue allograft transplantation.  Transplant Proc . 1998;  30 2721-2723
    CrossrefPubMedGoogle Scholar
  • 134 Grotz W H, Mundinger F A, Rasenack J. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients.  Nephrol Dial Transplant . 1995;  10 2096-2100
    PubMedGoogle Scholar
  • 135 Shane E, Rivas M, McMahon D J. Bone loss and turnover after cardiac transplantation.  Journal of Clinical Endocrinology and Metabolism . 1997;  82 1497-1506
    CrossrefPubMedGoogle Scholar
  • 136 Danovitch G. Immunosuppressant induced metabolic toxicities.  Transplant Review . 2000;  14
    PubMedGoogle Scholar
  • 137 Ingle G R, Sievers T M, Holt C D. Sirolimus: continuing the evolution of transplant immunosuppression.  Ann Pharmacother . 2000;  34 1044-1055
    CrossrefPubMedGoogle Scholar
  • 138 Zimmerman J J, Kahan B D. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration.  J Clin Pharmacol . 1997;  37 405-415
    PubMedGoogle Scholar
  • 139 Yatscoff R W. Pharmacokinetics of rapamycin.  Transplant Proc . 1996;  28 970-973
    PubMedGoogle Scholar
  • 140 Wyeth Ayerst Laboratories: Rapamune oral solution (sirolimus) package insert. Princeton, NJ 1999
    Google Scholar
  • 141 Groth C G, Brent L B, Calne R Y. Historic landmarks in clinical transplantation: conclusions from the consensus conference at the University of California, Los Angeles.  World J Surg . 2000;  24 834-843
    CrossrefPubMedGoogle Scholar
  • 142 Kaplan B, Meier-Kriesche H U, Napoli K L, Kahan B D. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.  Clin Pharmacol Ther . 1998;  63 48-53
    CrossrefPubMedGoogle Scholar
  • 143 Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients [letter].  N Engl J Med . 2000;  343 225-226
    CrossrefPubMedGoogle Scholar
  • 144 Mahalati K, Murphy D M, West M L. Bronchiolitis obliterans and organizing pneumonia in renal transplantation recipients.  Transplantation . 2000;  69 1531-1532
    PubMedGoogle Scholar
  • 145 Singer S J, Tiernan R, Sullivan E J. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients.  N Engl J Med . 2000;  343 1815-1816
    CrossrefPubMedGoogle Scholar
  • 146 Kreis H, Cisterne J M, Land W. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.  Transplantation . 2000;  69 1252-1260
    PubMedGoogle Scholar
  • 147 Doyle R L, Hertz M I, Dunitz J M. RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis.  J Heart Lung Transpl . 2001;  20(3) 330-339
    PubMedGoogle Scholar
  • 148 Fahrni J A, Berry G J, Morris R E, Rosen G D. Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model.  Transplantation . 1997;  63 533-537
    PubMedGoogle Scholar
  • 149 Reichenspurner H, Soni V, Nitschke M. Obliterative airway disease after heterotopic tracheal xenotransplantation: pathogenesis and prevention using new immunosuppressive agents.  Transplantation . 1997;  64 373-383
    PubMedGoogle Scholar
  • 150 Burk M L, Matuszewski K A. Muromonab-CD3 and antithymocyte globulin in renal transplantation.  Ann Pharmacother . 1997;  31 1370-1377
    PubMedGoogle Scholar
  • 151 Schroeder T J, Hariharan S, First M R. Antibody response to OKT3 and methods for monitoring.  Transplant Proc . 1993;  25 77-80
    PubMedGoogle Scholar
  • 152 Chatenoud L, Ferran C, Legendre C. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids.  Transplantation . 1990;  49 697-702
    PubMedGoogle Scholar
  • 153 Todd P A, Brogden R N. Muromonab CD3. A review of its pharmacology and therapeutic potential.  Drugs . 1989;  37 871-899
    PubMedGoogle Scholar
  • 154 Swinnen L J, Costanzo-Nordin M R, Fisher S G. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients [see comments].  N Engl J Med . 1990;  323 1723-1728
    CrossrefPubMedGoogle Scholar
  • 155 Kriett J M, Smith C M, Hayden A M. Lung transplantation without the use of antilymphocyte antibody preparations.  J Heart Lung Transplant . 1993;  12 915-923
    PubMedGoogle Scholar
  • 156 Ross D J, Jordan S C, Nathan S D, Kass R M, Koerner S K. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation: a plea for multicenter immunosuppressive trials [see comments].  Chest . 1996;  109 870-873
    PubMedGoogle Scholar
  • 157 Bonnefoy-Berard N, Revillard J P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.  J Heart Lung Transplant . 1996;  15 435-442
    PubMedGoogle Scholar
  • 158 Kesten S, Rajagopalan N, Maurer J. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation.  Transplantation . 1996;  61 427-430
    CrossrefPubMedGoogle Scholar
  • 159 Snell G I, Esmore D S, Williams T J. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation [see comments].  Chest . 1996;  109 874-878
    CrossrefPubMedGoogle Scholar
  • 160 Onrust S V, Wiseman L R. Basiliximab.  Drugs . 1999;  57 207-214
    CrossrefPubMedGoogle Scholar
  • 161 Wiseman L R, Faulds D. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.  Drugs . 1999;  58 1029-1042
    CrossrefPubMedGoogle Scholar
  • 162 Nashan B, Moore R, Amlot P, Schmidt A G, Abeywickrama K, Soulillou J P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.  Lancet . 1997;  350 1193-1198
    CrossrefPubMedGoogle Scholar
  • 163 Amstadt C A, Bhorade S M, McCabe M A, Vigneswaran W, Garrity E R. The efficacy of daclizumab, an anti-interleukin receptor antibody, in the prevention of acute rejection in lung transplantation.  Transplantation . 1999;  67(7)(suppl) S103
    PubMedGoogle Scholar
  • 164 Jover J, Latifi H, Frost A. Preliminary data regarding the use of interleukin-2-receptor antibody (Daclizumab) in lung transplantation.  Transplantation . 1999;  67(7)(suppl) S110
    PubMedGoogle Scholar
  • 165 Takao M, Higenbottam T W, Audley T, Otulana B A, Wallwork J. Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart-lung transplant patients.  Transplant Proc . 1995;  27 1284-1285
    PubMedGoogle Scholar
  • 166 O'Riordan T G, Iacono A, Keenan R J. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients.  Am J Respir Crit Care Med . 1995;  151 516-521
    PubMedGoogle Scholar
  • 167 Iacono A T, Keenan R J, Duncan S R. Aerosolized cyclosporine in lung recipients with refractory chronic rejection.  Am J Respir Crit Care Med . 1996;  153 1451-1455
    PubMedGoogle Scholar
  • 168 Keenan R J, Zeevi A, Iacono A T. Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics.  Surgery . 1995;  118 385-391
    PubMedGoogle Scholar
  • 169 Iacono A T, Smaldone G C, Keenan R J. Dose-related reversal of acute lung rejection by aerosolized cyclosporine.  Am J Respir Crit Care Med . 1997;  155 1690-1698
    PubMedGoogle Scholar
  • 170 Keenan R J, Iacono A, Dauber J H. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients.  J Thorac Cardiovasc Surg . 1997;  113 335-341
    CrossrefPubMedGoogle Scholar
  • 171 Cahill B C, O'Rourke M K, Strasburg K A. Methotrexate for lung transplant recipients with steroid-resistant acute rejection.  J Heart Lung Transplant . 1996;  15 1130-1137
    PubMedGoogle Scholar
  • 172 Dusmet M, Maurer J, Winton T, Kesten S. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients.  J Heart Lung Transplant . 1996;  15 948-954
    PubMedGoogle Scholar
  • 173 O'Hagan A R, Stillwell P C, Arroliga A, Koo A. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation.  Chest . 1999;  115 1459-1462
    CrossrefPubMedGoogle Scholar
  • 174 Diamond D A, Michalski J M, Lynch J P, Trulock III P E. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation.  Int J Radiat Oncol Biol Phys . 1998;  41 795-800
    CrossrefPubMedGoogle Scholar
  • 175 Heshmati F, Guillemain R, Achkar A. Traitement du rejet de greffe d'organe par photochimiotherapie extra-corporelle.  Ann Med Interne . 1994;  145 312-315
    PubMedGoogle Scholar
  • 176 Andreu G, Achkar A, Couetil J P. Extracorporeal photochemotherapy treatment for acute lung rejection episode.  J Heart Lung Transplant . 1995;  14 793-796
    PubMedGoogle Scholar
  • 177 Carr T, Bolman III M R, Perry E. Photopheresis for chronic rejection of lung transplant in a small pediatric patient.  J Clin Apheresis . 1995;  10 1995
    PubMedGoogle Scholar
  • 178 Slovis B S, Loyd J E, King Jr E L. Photopheresis for chronic rejection of lung allografts.  N Engl J Med . 1995;  332 962
    CrossrefPubMedGoogle Scholar
  • 179 Date H, Lynch J P, Sundaresan S, Patterson G A, Trulock E P. The impact of cytolytic therapy on bronchiolitis obliterans syndrome.  J Heart Lung Transplant . 1998;  17 869-875
    PubMedGoogle Scholar
      >